No press releases found.
Market Chameleon (Wed, 1-Apr 5:52 AM ET)
Market Chameleon (Wed, 1-Apr 3:54 AM ET)
Cyclerion's Strategic Medsteer Partnership Paves Path to 2026 CYC-126 Depression Trial
Market Chameleon (Tue, 6-Jan 4:54 AM ET)
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. The company focuses on enabling the full therapeutic potential of next-generation sGC stimulators and neuropsychiatric diseases. Its pipeline products include Olinciguat, Praliciguat, and others.
Cyclerion Therapeutics trades on the NASDAQ stock market under the symbol CYCN.
As of September 18, 2026, CYCN stock price was flat at $3.36 with million shares trading.
CYCN has a beta of 3.52, meaning it tends to be more sensitive to market movements. CYCN has a correlation of 0.02 to the broad based SPY ETF.
CYCN has a market cap of $15.73 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, CYCN traded as high as $66.29 and as low as $3.36.
The top ETF exchange traded funds that CYCN belongs to (by Net Assets): VXF.
CYCN has underperformed the market in the last year with a price return of -79.5% while the SPY ETF gained +16.8%. CYCN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -85.0% and -88.7%, respectively, while the SPY returned +2.3% and -0.9%, respectively.
CYCN support price is $3.10 and resistance is $3.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CYCN shares will trade within this expected range on the day.